ESTRO 2024 - Abstract Book

S2645

Clinical - Urology

ESTRO 2024

Four deaths occurred within 6 months post SBRT and were not related to radiotherapy treatment. Grade ≥ 3 CTCAE and RTOG toxicity above baseline was reported in 7 patients, with up to 2 events potentially associated with SBRT. Median EQ-5D quality of life questionnaire score of 80 (IQR 65-90) was unchanged up to 6 months post treatment.

Conclusion:

In this primary endpoint analysis of TRAP trial we have demonstrated a PFS of 6.4 months after SBRT in prostate OPD, exceeding the hypothesized PFS of 4 months. Furthermore, over 40% of patients remained progression-free at 12 months. Treatment did not impact quality of life. Further analysis of biomarker panel including circulating DNA and whole body MRI imaging will promote better patient selection for SBRT.

Keywords: SBRT, prostate, oligoprogression

References: Funder: Prostate Cancer UK

3395

Proffered Paper

Acute toxicity from PACE-C comparing Stereotactic Body Radiotherapy (SBRT) with moderate hypofractionation (MHRT)

Alison Tree 1,2 , Victoria Hinder 3 , Andrew Chan 4 , Shaun Tolan 5 , Peter Ostler 6 , Hans Van Der Voet 7 , Kiran Kancherla 8 , Andrew Loblaw 9 , Olivia Naismith 10 , Suneil Jain 11 , Alexander Martin 12 , Derek Price 13 , Douglas Brand 3 , William Chu 9 , John Armstrong 14 , Aileen Duffton 15 , John Staffurth 16 , Julia Pugh 3 , Georgina Manning 3 , Stephanie Brown 3 , Stephanie Burnett 3 , Clare Griffin 3 , Emma Hall 3 , Nicholas Van As 1,2 1 The Royal Marsden Hospitals NHS Foundation Trust, The Royal Marsden Hospital, London, United Kingdom. 2 The Institute of Cancer Research, The Institute of Cancer Research, London, United Kingdom. 3 The Institute of Cancer Research, Clinical Trials and Statistics Unit, London, United Kingdom. 4 University Hospitals Coventry & Warwickshire